MedPath

Trial to Assess Lacosamide as the First add-on Anti-epileptic Drug Treatment in Patients With Partial-onset Seizures

Phase 4
Completed
Conditions
Partial Epilepsies
Interventions
Registration Number
NCT00955357
Lead Sponsor
UCB Pharma
Brief Summary

To evaluate the efficacy and safety of oral Lacosamide as first add on treatment in subjects with uncontrolled partial-onset seizures after prior treatment with a monotherapy Antiepileptic Drug (AED) regimen compared to subjects who have received treatment with at least 2 AEDs.

Detailed Description

The study consisted of 3 Periods: Period 1: a 1-week Screening Phase, Period 2: a 30-week Treatment Phase (consisting of a 6-week Titration Phase and a 24-week Maintenance Phase), and Period 3: a 3-week Taper/Safety Follow-Up Phase.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
461
Inclusion Criteria

Group 1:

  • Subject has a diagnosis of epilepsy with simple partial seizures (motor component) and/or complex partial seizures with or without secondary generalization
  • Currently taking adequate monotherapy (defined as a single Antiepileptic Drug (AED) for at least 28 days prior to Screening) and has no history of AED polytherapy. Prior use of rescue medication (short-term intermittent use) is acceptable
  • Epilepsy diagnosis should be ≤24 months at the time of the Screening Visit
  • The minimum allowed seizure frequency at any time during the 12 weeks prior to the Screening Visit is ≥3 partial-onset seizures

Group 2:

  • Subject has a diagnosis of epilepsy with simple partial seizures (motor component) and/or complex partial seizures with or without secondary generalization
  • Currently taking 1 to 3 AEDs, and has tried at least 2 prior AED treatment regimens (concurrently or sequentially)
  • Epilepsy diagnosis should be ≥5 years at the time of the Screening Visit
  • The minimum allowed seizure frequency during the 12 weeks prior to the Screening Visit is ≥1 partial-onset seizure per 28 days
Exclusion Criteria
  • Previous use of Lacosamide
  • History of seizure disorder characterized primarily by isolated auras
  • History of primary generalized seizures
  • History of status epilepticus within last 12-months
  • History of cluster seizures during the 12 week period prior to Visit 1
  • Nonepileptic events, including pseudoseizures that could be confused with seizure
  • Lifetime history of suicide attempt or suicidal ideation in the past 6 months
  • Hypersensitivity to any component of Lacosamide
  • History of drug or alcohol abuse
  • History of an acute or subacutely progressive Central Nervous System (CNS) disease
  • Undergone cranial surgery within the last year prior to study entry
  • Concomitant treatment of Felbamate or previous Felbamate therapy within the last 6 months
  • Prior or concomitant Vigabatrin use

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
First Add-onLacosamideLacosamide added to first adequate monotherapy (no history of Antiepileptic Drug \[AED\] polytherapy) and epilepsy diagnosis \< or = 24 months at Screening.
Later Add-onLacosamideLacosamide added to 1 to 3 Antiepileptic Drugs (AEDs) (with tentatives of at least 2 prior AED treatment regimens) and epilepsy diagnosis \> or = 5 years at Screening.
Primary Outcome Measures
NameTimeMethod
The Proportion of Subjects Who Achieved "Seizure-free Status" During the First 12 Weeks of the Maintenance PhaseFrom Week 7 (end of Week 6) to end of Week 18

A subject will be considered seizure-free if the subject completes the first 12 weeks of the Maintenance Phase, reports zero seizures, and has no seizure data missing for any day during the period of time.

This study was intended to assess the efficacy outcomes in the First Add-On Group and the Later Add-On Group individually relative to historical data. Comparisons between the 2 groups should not be attempted and conclusions should not be drawn.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (109)

703

🇧🇬

Blagoevrad, Bulgaria

706

🇧🇬

Pleven, Bulgaria

700

🇧🇬

Sofia, Bulgaria

704

🇧🇬

Sofia, Bulgaria

707

🇧🇬

Sofia, Bulgaria

123

🇺🇸

Rancho Mirage, California, United States

103

🇺🇸

Irvine, California, United States

156

🇺🇸

Clearwater, Florida, United States

157

🇺🇸

Destin, Florida, United States

140

🇺🇸

Hollywood, Florida, United States

161

🇺🇸

Ocala, Florida, United States

108

🇺🇸

Atlanta, Georgia, United States

124

🇺🇸

Augusta, Georgia, United States

112

🇺🇸

Atlanta, Georgia, United States

115

🇺🇸

Macon, Georgia, United States

130

🇺🇸

Des Moines, Iowa, United States

128

🇺🇸

Flossmoor, Illinois, United States

118

🇺🇸

Rome, Georgia, United States

102

🇺🇸

Bowling Green, Kentucky, United States

117

🇺🇸

Paducah, Kentucky, United States

107

🇺🇸

Houma, Louisiana, United States

145

🇺🇸

Ruston, Louisiana, United States

162

🇺🇸

Waldorf, Maryland, United States

101

🇺🇸

Annapolis, Maryland, United States

136

🇺🇸

Pittsfield, Massachusetts, United States

144

🇺🇸

Springfield, Massachusetts, United States

109

🇺🇸

Brooklyn, New York, United States

114

🇺🇸

Paterson, New Jersey, United States

127

🇺🇸

West Seneca, New York, United States

133

🇺🇸

Brooklyn, New York, United States

158

🇺🇸

Charlotte, North Carolina, United States

134

🇺🇸

Akron, Ohio, United States

141

🇺🇸

Tulsa, Oklahoma, United States

150

🇺🇸

Canton, Ohio, United States

121

🇺🇸

Indiana, Pennsylvania, United States

149

🇺🇸

Orangeburg, South Carolina, United States

120

🇺🇸

Columbia, South Carolina, United States

152

🇺🇸

Spartanburg, South Carolina, United States

154

🇺🇸

Dallas, Texas, United States

146

🇺🇸

Tomball, Texas, United States

119

🇺🇸

Fredericksburg, Virginia, United States

503

🇦🇹

Wien, Austria

702

🇧🇬

Sofia, Bulgaria

701

🇧🇬

Varna, Bulgaria

735

🇨🇿

Litomerice, Czechia

732

🇨🇿

Ostrava-Hrabuvka, Czechia

708

🇧🇬

Sofia, Bulgaria

400

🇫🇮

Helsinki, Finland

402

🇫🇮

Oulu, Finland

733

🇨🇿

Ostrava, Czechia

734

🇨🇿

Trutnov, Czechia

930

🇩🇰

Aarhus, Denmark

401

🇫🇮

Tampere, Finland

610

🇫🇷

Strasbourg, France

611

🇫🇷

Toulon, France

521

🇬🇷

Athens, Greece

520

🇬🇷

Thessaloniki, Greece

552

🇮🇹

Faenza, Italy

559

🇮🇹

Pietra Ligure, Italy

546

🇮🇹

Gallarate, Italy

551

🇮🇹

Trieste, Italy

180

🇲🇽

Aguascalientes, Mexico

183

🇲🇽

Chihuahua, Mexico

184

🇲🇽

Ciudad Juarez, Mexico

185

🇲🇽

Chihuahua, Mexico

189

🇲🇽

Guadalajara, Mexico

181

🇲🇽

Mexico DF, Mexico

193

🇲🇽

Mexico DF, Mexico

195

🇲🇽

Mexico DF, Mexico

186

🇲🇽

Monterrey, Mexico

187

🇲🇽

Monterrey, Mexico

188

🇲🇽

Monterrey, Mexico

182

🇲🇽

Polanco, Mexico

815

🇷🇴

Bucarest, Romania

810

🇷🇴

Cluj-napoca, Romania

830

🇷🇺

Kazan, Russian Federation

814

🇷🇴

Oradea, Romania

813

🇷🇴

Targu Mures, Romania

831

🇷🇺

Kazan, Russian Federation

834

🇷🇺

Moscow, Russian Federation

833

🇷🇺

Novosibirsk, Russian Federation

598

🇪🇸

Terrassa, Barcelona, Spain

592

🇪🇸

Almeria, Spain

597

🇪🇸

Bajo Sevilla, Spain

590

🇪🇸

Barcelona, Spain

596

🇪🇸

Santiago de Compostela, Spain

594

🇪🇸

Valencia, Spain

599

🇪🇸

Valladolid, Spain

892

🇨🇭

Lausanne, Switzerland

713

🇹🇷

Adana, Turkey

714

🇹🇷

Ankara, Turkey

711

🇹🇷

Istanbul, Turkey

710

🇹🇷

Eskisehir, Turkey

719

🇹🇷

Istanbul, Turkey

717

🇹🇷

Izmir, Turkey

718

🇹🇷

Trabzon, Turkey

153

🇺🇸

Boston, Massachusetts, United States

705

🇧🇬

Sofia, Bulgaria

736

🇨🇿

Hradec Kralove, Czechia

737

🇨🇿

Praha 11, Czechia

139

🇺🇸

Bismarck, North Dakota, United States

541

🇮🇹

Napoli, Italy

557

🇮🇹

Prato, Italy

540

🇮🇹

Roma, Italy

549

🇮🇹

Roma, Italy

542

🇮🇹

Taranto, Italy

547

🇮🇹

Torino, Italy

151

🇺🇸

Kansas City, Missouri, United States

148

🇺🇸

Austin, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath